ResearchMoz added Latest Research Report titled " Global Postmenopausal Osteoporosis Drugs Market 2016-2020 " to it's Large Report database.
About the Postmenopausal Osteoporosis Drugs Market
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.
Technavios analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=720156
Covered in this report
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding postmenopausal osteoporosis
Epidemiology and demography
Risk factors
Symptoms
Diagnosis
Treatment
PART 06: Key buying criteria
PART 07: Pipeline scenario
TBRIA
Romosozumab (AMG785)
Odanacatib (MK-0822)
Abaloparatide SC/Abaloparatide transdermal patch
PHN-031 (PH3)
NB S101
Teriparatide ZP Patch (ZP-PTH)
Blosozumab (LY2541546)
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
About the Postmenopausal Osteoporosis Drugs Market
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.
Technavios analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=720156
Covered in this report
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding postmenopausal osteoporosis
Epidemiology and demography
Risk factors
Symptoms
Diagnosis
Treatment
PART 06: Key buying criteria
PART 07: Pipeline scenario
TBRIA
Romosozumab (AMG785)
Odanacatib (MK-0822)
Abaloparatide SC/Abaloparatide transdermal patch
PHN-031 (PH3)
NB S101
Teriparatide ZP Patch (ZP-PTH)
Blosozumab (LY2541546)
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment